Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment DCR-BCAT
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature β-catenin
Official Symbol CTNNB1
Mode of action PROT_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description For both the IHC and flow cytometry datasets, the tumor samples were derived from separate,independent in-life experiments. Loss of β-catenin protein after RNAi therapy (approximately 60% decrease in relative intensity) was homogeneous throughout the tumor section, and it was observed in both the cell membrane and the cytosol of B16F10 tumors. In thenative state, the tumors are negative for CD8, consistent with theirimmunologically cold status. After two rounds of DCR-BCAT treatment, CD8 staining was observed throughout the tumor.
PMID 30274786
Title RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade